Demyelinating events in early multiple sclerosis have inherent severity and recovery

Neurology

Volumn 72, Issue 7, 2009, Pages 602-608

  Mowry, E M ^a   Pesic, M ^a   Grimes, B ^b   Deen, S ^a   Bacchetti, P ^b   Waubant, E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID;

ADULT; ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; COHORT ANALYSIS; COMPARATIVE STUDY; CONVALESCENCE; FOLLOW UP; HOSPITALIZATION; MIDDLE AGED; MYELINATED NERVE; PATHOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; COHORT STUDIES; DEMYELINATING DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVE FIBERS, MYELINATED; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 61849161115     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000342458.39625.91     Document Type: Article

References (26)

1. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126: 770-782.
2. Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population based cohort: a 10-year follow-up study. Neurology 2004;62:51-59.
3. Phadke JG. Clinical aspects of multiple sclerosis in northeast Scotland with particular reference to its course and prognosis. Brain 1990; 113:1597-1628.
4. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study: 3: multivariate analysis of predictive factors and models of outcome. Brain 1991;114:1045-1056.
5. Amato MP, Ponziani G, Bartolozzi ML, Siracusa G. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999; 168:96-106.
6. Scott TF, Schramke CJ, Novero J, Chieffe C. Short-term prognosis in early relapsing remitting multiple sclerosis. Neurology 2000;55:689-693.
7. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-134.
8. Kurtzke JF, Beebe GW, Nagler B, Kurland LT, Auth TL. Studies on the natural history of multiple sclerosis: 8: early prognostic features of the later course of the illness J Chron Dis 1977;30:819-830.
9. Amato MP, Ponziani G. A prospective study on the prognosis of multiple sclerosis. Neurol Sci 2000;21:S831-S838.
10. West T, Wyatt M, High A, Bostrom A, Waubant E. Are initial demyelinating event recovery and time to second event under differential control? Neurology 2006;67:809-813.
11. Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992;326:581-588.
12. Deen S, Bacchetti P, High A, Waubant E. Predictors of the location of multiple sclerosis relapse. J Neurol Neurosurg Psychiatry 2008;79:1190-1193.
13. Polman CH, Reingold SG, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria." Ann Neurol 2005;58:840-846.
14. Comi G, Filippi M, Wolinsky J. European/Canadian mul-ticenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-297.
15. Waubant E, Goodkin DE, Sloan R, Andersson PB. A pilot study of MRI activity before and during interferon beta-la therapy. Neurology 1999;53:874-876.
16. Mowry EM, Deen S, Malikova I, Pelletier J, Bacchetti P, Waubant E. The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry Epub 2008 December 9.
17. Panitch H, Goodin DS, Francis G, et al. EVIDENCE Study Group: randomized, comparative study of interferon beta-la treatment regimens in MS: the EVIDENCE trial. Neurology 2002;59:1496-1506.
18. Lucchinetti C, Brack W, Parisi J, Scheithauer B, Rodriguez M, Lassman H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyeli-nation. Ann Neurol 2000;47:707-717.
19. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
20. IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-661.
21. Cree BA, Khan O, Bourdette D, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2004;63:2039-2045.
22. Kaufman MD, Johnson SK, Moyer D, Bivens J, Norton HJ. Multiple sclerosis: severity and progression rate in African Americans compared to whites. Am J Phys Med Rehab 2003;82:582-590.
23. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? Neurology 2006;66:1235-1240.
24. Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, et al. Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Mult Scler 2003;9:293-298.
25. Mowry EM, Pesic M, Deen SR, Grimes B, Bacchetti P, Waubant E. Age, race, and initial demyelinating events with fewer affected functional systems predict an increased hazard of early relapse in multiple sclerosis. Mult Scler 2008;14:P563. Abstract.
26. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficits in multiple sclerosis. Neurology 2003;61: 1528-1532.